Isabel Bretones-Soria
St. Laurent
QC, Canada
QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.
Journal: International journal of molecular sciences
Published: February 08, 2026
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.
Journal: Research square
Published: August 06, 2025
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.
Journal: Nature communications
Published: July 06, 2025
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Journal: Nature communications
Published: August 22, 2024
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification.
Journal: Cancer gene therapy
Published: January 20, 2024
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.
Journal: Nature reviews. Cancer
Published: November 27, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Journal: Research square
Published: July 28, 2023
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Journal: Nature communications
Published: June 22, 2023
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations.
Journal: Science advances
Published: September 07, 2022
CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 01, 2022
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.
Journal: Molecular cancer therapeutics
Published: February 08, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
Journal: Nature communications
Published: October 19, 2021
Last Updated: 09/26/2026